Assessment of the levels of angiogenetic factors, such as vascular endothelial or placenta growth factor in both serum and hematoma, could shed light on the pathophysiological basis by which cSDH formation and healing may be altered by ACE inhibitor use. Here, ACE is linked to hematoma.